Business Standard

Zydus Lifesciences Q4 net dips to 24% Rs 397 cr, revenue up 5%

Company says operational performance came amid geopolitical turmoil resulting in supply chain challenges and inflationary pressures

Cadila Healthcare changes name to Zydus Lifesciences Limited
Premium

Vinay Umarji Ahmedabad
On the back of growth in domestic and emerging markets formulations businesses, Zydus Lifesciences Ltd. posted a net profit of Rs 397.4 crore for the fourth quarter ended March 31, 2022 of financial year 2021-22 (FY22).

The pharma major had reported a net profit of Rs 679 crore for the fourth quarter ended March 31, 2021 of the previous financial year 2020-21 (FY21).  However, when adjusted for one-time inventory provision, exceptional and non-recurring items as well as profit from discontinued operations, the net profit for Q4 of FY21 stood at Rs 525 crore.

Revenue from operations for the quarter grew

What you get on BS Premium?

  • Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
  • Pick your 5 favourite companies, get a daily email with all news updates on them.
  • Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
  • Preferential invites to Business Standard events.
  • Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.
VIEW ALL FAQs

Need More Information - write to us at assist@bsmail.in